Empire Genomics has developed a technology called array-based Comparative Genomic Hybridization (aCGH) that determines gains or losses of genetic material to streamline screening for chromosomal defects such as Down's syndrome. DNA microarray technology places DNA representing genes and chromosomes on a slide for comparison with a normal set, and the Reprogenetics and Empire Genomics collaboration has resulted in the successful application of this technology to preimplantation genetic screening.
"With our advanced genomic technology we are able to screen all of the chromosomes from a single cell obtained from an embryo, as opposed to conventional techniques that selectively screen just half of the chromosomes, and for use in IVF, we can complete the process rapidly to allow for embryo screening before implantation has to take place," said Norma Nowak, Ph.D., Empire Genomics' founder and CSO. "The collaboration with Reprogenetics has allowed us to optimize this technique and expand the abilities to detect other microdeletion occurrences."
The abstract, entitled "Comprehensive Aneuploidy Screening in Single Cells Using Microarray Comparative Genomic Hybridization Methods: Implications for Preimplantation Genetic Diagnosis," will be presented on Wednesday, October 17th at 3:30pm. These data to be presented demonstrate reproducible genomic profiling of single cells. Trisomies were identified in chromosomes 13, 15, 16, 18 and 21, which are associated with Down's syndrome, poor fetal development and several rare conditions. Sex mismatched DNA was also identified. With this technology more aneuploidy could be identified and thus avoided compared to conventional screening techniques.
ABOUT EMPIRE GENOMICS
Empire Genomics, based in Buffalo, New York, utilizes proprietary
techniques to identify and quantify chromosomal abnormalities. Specifically
the company has evolved array-based
Copyright©2007 PR Newswire.
All rights reserved